A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer
NCT00058526
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
61
Enrollment
INDUSTRY
Sponsor class
Conditions
Neoplasms, Breast
Interventions
BIOLOGICAL:
Immunotherapeutic SB719125 (Primary)
Sponsor
GlaxoSmithKline